Health Care [ 5/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
Atai Life SciencesN. V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder.
It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD.
In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders.
ATAI Life SciencesN. V. was founded in 2018 and is headquartered in Berlin, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 25 | -0.14 Increased by +61.11% | -0.12 Decreased by -16.67% |
| May 13, 25 | -0.15 Increased by +11.76% | -0.18 Increased by +16.67% |
| Mar 26, 25 | -0.24 Decreased by -100.00% | -0.15 Decreased by -60.00% |
| Nov 5, 24 | -0.16 Increased by +42.86% | -0.16 |
| Aug 6, 24 | -0.36 Decreased by -71.43% | -0.16 Decreased by -125.00% |
| May 15, 24 | -0.17 Increased by +19.05% | -0.18 Increased by +5.56% |
| Mar 28, 24 | -0.12 Increased by +57.14% | -0.16 Increased by +25.00% |
| Nov 14, 23 | -0.28 Decreased by -27.27% | -0.20 Decreased by -40.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 719.00 K Increased by +163.37% | -27.73 M Increased by +51.62% | Decreased by -3.86 K% Increased by +81.63% |
| Mar 31, 25 | 1.55 M Increased by +N/A% | -26.43 M Increased by +1.06% | Decreased by -1.70 K% Decreased by N/A% |
| Dec 31, 24 | -5.00 K Decreased by -127.78% | -38.96 M Decreased by -112.98% | Increased by +779.16 K% Increased by +866.72% |
| Sep 30, 24 | 40.00 K Decreased by -54.02% | -26.29 M Decreased by -159.41% | Decreased by -65.72 K% Decreased by -229.22% |
| Jun 30, 24 | 273.00 K Increased by +58.72% | -57.31 M Decreased by -73.45% | Decreased by -20.99 K% Decreased by -9.28% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -26.71 M Increased by +19.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 18.00 K Decreased by -52.63% | -18.29 M Increased by +59.64% | Decreased by -101.62 K% Increased by +14.80% |
| Sep 30, 23 | 87.00 K Increased by +262.50% | 44.24 M Increased by +232.99% | Increased by +50.86 K% Increased by +136.69% |